Literature DB >> 10334437

Three-dimensional color Doppler: a clinical study in patients with mitral regurgitation.

R De Simone1, G Glombitza, C F Vahl, J Albers, H P Meinzer, S Hagl.   

Abstract

OBJECTIVES: The purpose of this study was to assess the clinical feasibility of three-dimensional (3D) reconstruction of color Doppler signals in patients with mitral regurgitation.
BACKGROUND: Two-dimensional (2D) color Doppler has limited value in visualizing and quantifying asymmetric mitral regurgitation. Clinical studies on 3D reconstruction of Doppler signals in original color coding have not yet been performed in patients. We have developed a new procedure for 3D reconstruction of color Doppler.
METHODS: We studied 58 patients by transesophageal 3D echocardiography. The jet area was assessed by planimetry and the jet volumes by 3D Doppler. The regurgitant fractions, the volumes, and the angiographic degree of mitral regurgitation were assessed in 28 patients with central jets and compared with those of 30 patients with eccentric jets.
RESULTS: In all patients, jet areas and jet volumes significantly correlated with the angiographic grading (r = 0.73 and r = 0.90), the regurgitant fraction (r = 0.68 and r = 0.80) and the regurgitant volume (r = 0.66 and r = 0.90). In patients with central jets, significant correlations were found between jet area and angiography (r = 0.86), regurgitant fraction (r = 0.64) and regurgitant volume (r = 0.78). No significant correlations were found between jet area and angiography (r = 0.53), regurgitant fraction (r = 0.52) and regurgitant volume (r = 0.53) in the group of patients with eccentric jets. In contrast, jet volumes significantly correlated with angiography (r = 0.90), regurgitant fraction (r = 0.75) and regurgitant volume (r = 0.88) in the group of patients with eccentric jets.
CONCLUSIONS: Three-dimensional Doppler revealed new images of the complex jet geometry. In addition, jet volumes, assessed by an automated voxel count, independent of manual planimetry or subjective estimation, showed that 3D Doppler is also capable of quantifying asymmetric jets.

Entities:  

Mesh:

Year:  1999        PMID: 10334437     DOI: 10.1016/s0735-1097(99)00041-8

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  7 in total

Review 1.  Quantitative assessment of mitral insufficiency: its advantages and disadvantages.

Authors:  Anna Paszczuk; Susan E Wiegers
Journal:  Heart Fail Rev       Date:  2006-09       Impact factor: 4.214

2.  [Three-dimensional echocardiography in cardiac surgery. Current status and perspectives].

Authors:  M R Hoda; T Schwarz; I Wolf; S Mottl-Link; H P Meinzer; M Karck; R De Simone
Journal:  Chirurg       Date:  2007-05       Impact factor: 0.955

3.  Real-time three-dimensional color Doppler flow imaging: an improved technique for quantitative analysis of aortic regurgitation.

Authors:  Qing Lu; Xiatian Liu; Mingxing Xie; Xinfang Wang; Jing Wang; Lei Zhuang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2006

Review 4.  Three-dimensional echocardiography. New possibilities in mitral valve assessment.

Authors:  Jorge Solis; Marta Sitges; Robert A Levine; Judy Hung
Journal:  Rev Esp Cardiol       Date:  2009-02       Impact factor: 4.753

5.  In vitro validation of real-time three-dimensional color Doppler echocardiography for direct measurement of proximal isovelocity surface area in mitral regurgitation.

Authors:  Stephen H Little; Stephen R Igo; Bahar Pirat; Marti McCulloch; Craig J Hartley; Yukihiko Nosé; William A Zoghbi
Journal:  Am J Cardiol       Date:  2007-04-09       Impact factor: 2.778

6.  Three-dimensional echocardiography in valve disease.

Authors:  Chiara Colombo; Gloria Tamborini; Mauro Pepi; Marina Alimento; Cesare Fiorentini
Journal:  Heart Int       Date:  2007-06-15

Review 7.  Role of modern 3D echocardiography in valvular heart disease.

Authors:  Takahiro Shiota
Journal:  Korean J Intern Med       Date:  2014-10-31       Impact factor: 2.884

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.